Publications by authors named "Danja Monje"

Claim this Profile
A
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.
Sylvia Haas, Lorenzo G Mantovani, Reinhold Kreutz, Danja Monje, Jonas Schneider

Res Pract Thromb Haemost· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
Keith A A Fox, Sonia S Anand, Victor Aboyans, Martin R Cowie, E Sebastian Debus, Danja Monje

Am Heart J· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
Reinhold Kreutz, Lorenzo G Mantovani, Sylvia Haas, Danja Monje, Jonas Schneider

Thromb Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Kerstin Folkerts, Martin Gebel, Danja Monje

Eur J Intern Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA.
Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje

TH Open· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis.
Stefan Cano, Lorenzo Mantovani, Kerstin Folkerts, Martin Gebel, Kurtulus Sahin, Danja Monje

TH Open· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
Alexander G G Turpie, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje

Thromb Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE.
Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje

TH Open· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real life studies and good clinical practice - Authors' reply.
Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje

Lancet Haematol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje

Lancet Haematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis